Dr. Ting Deng 邓婷
Chief Physician, Lecturer
Department of Medical Oncology for Digestive Tumors, Tianjin Medical University Cancer Institute & Hospital, Tianjin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical oncology for gastrointestinal cancers, including gastric, colorectal, esophageal, pancreatic, and gallbladder/bile duct cancers. Focuses on neoadjuvant and adjuvant chemotherapy, as well as chemotherapy, targeted therapy, and immunotherapy for advanced tumors.
Dr. Deng has long engaged in clinical medical oncology. Expertise includes preoperative neoadjuvant chemotherapy and postoperative adjuvant chemotherapy for gastrointestinal malignancies, along with chemotherapy, targeted therapy, and immunotherapy for patients with advanced tumors.
Professional roles
- Vice Chair, Youth Committee of Clinical Drug Research Professional Committee, China Anti-Cancer Association
- Member, Supportive Care Professional Committee, China Anti-Cancer Association
- Member, Chemotherapy Professional Committee, China Anti-Cancer Association
- Member, Youth Expert Committee, Chinese Society of Clinical Oncology (CSCO)
Name order: in Chinese the family name comes first (Deng Ting). Papers usually list the name as Ting Deng or Deng T.
Selected publications
106 papers on PubMed matched by name and affiliation; 14 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Gastroenterol, 2026 (senior author): Inhibiting METTL3 synergizes with Notch blockade to treat ESCC by targeting cancer stemness via m6A-JAG2. PubMed 42274788
- BMC Cancer, 2025 (senior author): The combination of anti-PD-1 antibodies, trastuzumab and chemotherapy may improve the outcome of some patients with HER2-positive alpha-fetoprotein-producing gastric cancer: a retrospective real-world analysis from a single center. PubMed 41073956
- Cancer Immunol Immunother, 2024 (first author): Combinational zimberelimab plus lenvatinib and chemotherapy for alpha-fetoprotein elevated, advanced gastric cancer patients (AFPGC): a phase 1 dose-escalation study. PubMed 38833154
- BMC Cancer, 2024 (senior author): Chemotherapy re-use versus anti-angiogenic monotherapy as the third-line treatment of patients with metastatic colorectal cancer: a real-world cohort study. PubMed 38443891
- BMC Cancer, 2024 (senior author): Combined score based on plasma fibrinogen and platelet-lymphocyte ratio as a prognostic biomarker in esophageal squamous cell carcinoma. PubMed 38389042
- Invest New Drugs, 2023 (first author): Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1-3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trial. PubMed 37889382
- Ther Adv Chronic Dis, 2023 (first author): Third-line treatment patterns and clinical outcomes for metastatic colorectal cancer: a retrospective real-world study. PubMed 37720594
- Ther Adv Med Oncol, 2023 (first author): Safety, tolerability, and pharmacokinetics of an anti-LAG-3 antibody SHR-1802 in patients with advanced solid tumors: a phase I dose-escalation and dose-expansion study. PubMed 37529157
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion